TCR2 Therapeutics Inc(NASDAQ:TCRR) 
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is...
Website: http://www.tcr2.com
Founded: 2015
Full Time Employees: 109
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2022-12-01
P
O 1.39
H 1.57
L 1.35
C 1.44
V 475,468
10EMA 1.44
20EMA 1.44
60EMA 1.44
120EMA 1.44
250EMA 1.44